Moral Investing's  Instablog

Moral Investing
Send Message
Private investor.
  • Deeper Research: Belviq + Phentermine Equals What? 9 comments
    Aug 30, 2013 1:02 PM | about stocks: ARNA

    Recently, a majority of investors do not know that Arena published a patent application for Belviq plus Phentermine:


    United States Patent Application 20130217677

    The reason this is relevant to investors is the data results Arena reported in graphs in preclinical trials from the Belviq chemical family plus Phentermine.

    The following graph (page -13 see patent link above) show four arms in the study: Placebo, Phentermine alone, Belviq alone, and a combination(s).

    As you can see the last version from the Belviq chemistry family demonstrated a "supra additive effect" especially in the last chart (above). Yes, these are preclinical studies, but perhaps you will now understand why Eisai was anxious to join Arena on a future drug many call "Bel-Phen".

    Financially speaking, this is a key reason why I am a long investor.

    If you like this kind of information, please FOLLOW ME.

    Disclosure: I am long ARNA.

    Additional disclosure: Non-published blog post.

    Stocks: ARNA
Back To Moral Investing's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (9)
Track new comments
  • PEhrlich
    , contributor
    Comments (1702) | Send Message
    When they say they are developing with 15 mg phentermine, is that phentermine BID (30 mg per day) or 15 mg QD?
    30 Aug 2013, 01:33 PM Reply Like
  • TevisM
    , contributor
    Comments (63) | Send Message
    Moral, don't you mean to say "supra additive effect" rather than "supra addictive effect"?
    30 Aug 2013, 03:23 PM Reply Like
  • Moral Investing
    , contributor
    Comments (66) | Send Message
    Author’s reply » Thanks. Correction made.
    30 Aug 2013, 03:38 PM Reply Like
  • michelodu
    , contributor
    Comments (41) | Send Message
    Why don't you rotate your figure? If you want to make a big impact, be a perfectionist about these details, as persuasive as is the data.
    30 Aug 2013, 03:49 PM Reply Like
  • Upbeat
    , contributor
    Comments (786) | Send Message
    It's nice to have an alternative to Osborne, who is obsessed about a stock he claims represents just 5% of his portfolio and is the most negative long I have ever read. Even good news comes with downer qualifications.
    Hopefully other objective pros and cons will join in here.
    30 Aug 2013, 06:22 PM Reply Like
  • bakemann
    , contributor
    Comments (33) | Send Message
    really , how soon could this be on the market 2017 ? or is that to early
    and what would there partner have to say about that since they have no contract for sharing rev. for this bel-pfen combo. and since VVUS has REMS and outcomes studies for there phen combo, what does this mean for bel-phen? you see the problems adding up. Really it sounds good and it may work, but isn't this just a pipe dream ?
    30 Aug 2013, 07:14 PM Reply Like
  • mightykay
    , contributor
    Comments (3) | Send Message
    I think it is on the market if a doctor wants to prescribe off lable
    1 Sep 2013, 03:25 AM Reply Like
  • steveh8000
    , contributor
    Comments (163) | Send Message
    Least we not forget.....the FDA approved the VVUS combo already. It's on the market. I think we have a much safer compound. An off label doctor's decision to combine two scripts for certain patients is a big plus for Belviq. I see early combo treatment for 3 months, and then on to Belviq maintenance.
    31 Aug 2013, 04:58 AM Reply Like
  • BudTuba
    , contributor
    Comments (34) | Send Message
    I appreciate your analysis and feel it should be shared on Facebook by readers to start our own advertising campaign for Belviq.
    2 Oct 2013, 07:44 PM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.